Funktionelle Neurogeriatrie

Die Forschungsgruppe funktionelle Neurogeriatrie untersucht motorische Funktionseinschränkungen bei Älteren und Patienten mit neurodegenerativen Erkrankungen. Es kommen dabei modernste Detektionssysteme und Algorithmen zur Anwendung. Der primäre Fokus ist dabei darauf gerichtet, den Einfluss von kognitiven Einschränkungen auf Bewegungsmuster zu beschreiben, und diese zu trainieren.

Forschungsprojekte
Mitarbeiter
Publikationen
Ambulanz

SENSE-PARK

 

Im Rahmen eines 3-jährigen EU-geförderten ICT-Projektes (FP7, SENSE-PARK) entwickeln, testen und validieren wir ein Sensor-Informationssystem für Parkinson-Patienten. Dieses System besteht aus einzelnen Modulen und soll sich möglichst "unauffällig" in den Alltag der Anwender integrieren lassen. Ein wichtiger Aspekt dieses Projektes ist die zentrale Miteinbindung von Parkinson-Patienten als Partner in die Projektentwicklung und -durchführung. Partner aus England, Deutschland, Norwegen und Portugal sind involviert. Aus dem Projekt hat sich ein Konsortium entwickelt, welches die gewonnenen Erkenntnisse aus SENSE-PARK weiter entwickelt.

Projektleiter: Dr. Holm Graessner
Wissenschaftlicher Leiter: Prof. Walter Maetzler



Moving beyond

 

Dieses EU-geförderte ITN-Projekt Moving Beyond fokussiert auf ein verbessertes Verständnis von supraspinalen Kontrollmechanismen von Gehen und Gleichgewicht bei älteren Menschen und Parkinson-Patienten, und auf therapeutische Optionen, wenn diese Mechanismen nicht mehr gut funktionieren. Partner aus England (Prof. John Rothwell, UCL), Deutschland (Bosch Healthcare), Israel (Prof. Jeffrey M. Hausdorff, Sourasky Medical Center, Tel Aviv) Schweden (Prof. Sten Grillner, Karolinska Institutet, Stockholm), der Schweiz (HOCOMA) und den Niederlanden (Prof. Bastiaan R. Bloem, University of Nijmegen; McRoberts, MOTEK Medical) arbeiten bei diesem Projekt mit.

Projektleiter: Prof. Walter Maetzler


Protein-Clearance-Aspekte bei neurodegenerativen Erkrankungen

 

Protein-Clearance (am besten mit "Protein-Abbau" oder "Protein-Beseitigung" zu übersetzen) spielt eine wichtige Rolle bei der Erhaltung der Integrität von Nervenzellen. Immer mehr Anzeichen deuten darauf hin, dass eine schlecht oder nicht funktionierende Protein-Clearance in den meisten - wenn nicht in allen - neurodegenerativen Erkrankungen grundlegend zu funktionellen und strukturellen Veränderungen beiträgt, die schließlich zu klinischen Symptomen führen. Wir interessieren uns für Transport-Proteine des zentralen Nervensystems und deren Assoziation mit dem Auftreten von klinischen Symptomen und Amyloid-Erkrankungen. Unser besonderer Fokus liegt auf Proteinen, die in Astrozyten und Microglia exprimiert werden, und auf Aspekten der Autoimmunität bei Personen mit erhöhtem Risiko für, und Patienten mit Parkinson- oder Alzheimer-Erkrankung. Unsere Arbeit wird wesentlich unterstützt von der Neuro-Biobank der Abteilung Neurodegeneration des Hertie-Instituts für klinische Hirnforschung.


Mechanistische Aspekte der Assoziation von Vestibulo-Okulärer Reflex-Suppression und Stürzen im älteren Menschen

 

Im Rahmen dieser Studie werden verschiedene neurogeriatrische Risikogruppen für Stürze zu 2 Zeitpunkten untersucht, es ist eine interventionelle Studie geplant. Ziel dieses Projektes ist es, den Einfluss von vestibulo-okulären Interaktionen (VOR, VOR-Suppression) auf Balance- und Gangmuster in neurogeriatrischen Risikogruppen und die Assoziation zu Stürzen zu verstehen. Diese Studie wird in enger Kooperation mit dem Team um Prof. Clemens Becker, Abteilung für Geriatrische Rehabilitation des Robert-Bosch-Krankenhauses Stuttgart durchgeführt.

Kontakt: Dr. med. Karin Srulijes.


ABC-PD

 

Diese Longitudinalstudie untersucht, ob und inwiefern eine im Liquor festgestellte Alzheimer-Pathologie das Fortschreiten kognitiver Einschränkungen bei Parkinson-Patienten voraussagen kann.

Kontakt: Dr. Inga Liepelt-Scarfone, Maren Rüdiger-Albers (07071 29 85711) und Susanne Nussbaum (07071 29 83621/83734).


Biochemische Marker von klinischem und prodromalem Parkinsonsyndrom

 

Diese Neuroalliance-geförderte Studie untersucht das Potential von bereits bekannten (und auch noch nicht bekannten aber vielversprechenden) Markern für idiopathisches Parkinsonsyndrom in Nervenwasser und Serum sowie Blutzellen, die Krankheit schon vor dem klinischen "Ausbruch" detektieren zu können. Dieses Projekt wird in Kooperation mit UCB (Dr. André da Costa durchgeführt.

Lokale Projektleiterin: Prof. Daniela Berg

 

 

 
Name
Arbeitsgruppe
Telefon
E-Mail
 Felix Bernhard
Felix Bernhard
Functional Neurogeriatrics
07071 29-83621 
 Morad Elshehabi
Morad Elshehabi
Functional Neurogeriatrics
07071 29-83621 
 Tanja Heger
Tanja Heger
Functional Neurogeriatrics
07071 29-83621 
 Markus Hobert
Markus Hobert
Functional Neurogeriatrics
07071 29-83621 
 Corina Maetzler
Corina Maetzler
Functional Neurogeriatrics
07071 29-81969 
Prof. Dr. Walter Maetzler
Prof. Dr. Walter Maetzler Research Group Leader
Functional Neurogeriatrics
07071 29-82047 
 Katrin Maier
Katrin Maier
Functional Neurogeriatrics
 
 Susanne Nussbaum
Susanne Nussbaum
Functional Neurogeriatrics
07071 29-83734 
 Minh-Hoang Pham
Minh-Hoang Pham
Functional Neurogeriatrics
 
 Hoang Minh Pham
Hoang Minh Pham
Functional Neurogeriatrics
07071 29-81969 
MSc, MD Dina Salkovic
MSc, MD Dina Salkovic
Functional Neurogeriatrics
07071 29-81969 
 Janet van Uem
Janet van Uem
Functional Neurogeriatrics
07071 29-83734 

Artikel

 

2016

 

Maetzler W, Klucken J, Kruger R, Muller T, Oertel W, Urban P, Warnecke T. Tragbare und aktiv vom Parkinson-Patienten genutzte Technologie im häuslichen Umfeld: Was bringt die Zukunft? Fortschritte der Neurologie Psychiatrie. 2016 accepted.

Maetzler W, Klucken J, Horne M. A clinical view on the development of technology-based tools in managing Parkinson’s disease. Movement Disorders. 2016 accepted.

Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, Wurster I, Rattay TW, Roncoroni L, Schaeffer E, Lerche S, Apel A, Deuschle C, Berg D. GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. PLoS One. 2016 11(3):e0149349.

Van Uem J, Maier KS, Hucker S, Scheck O, Hobert MA, Santos AT, Fagerbakke O, Larsen F, Ferreira JJ, Maetzler W. Twelve-Week Sensor Assessment in Parkinson’s Disease: Impact on Quality of Life. Movement Disorders. 2016 accepted.

Espay AJ, Bonato P, Nahab F, Maetzler W, Dean J, Klucken J, Eskofier B, Merola A, Horak F, Lang A, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little M, Litvan I, Simuni T, Dorsey R, Burack M, Kubota K, Kamondi A, Godinho C, Daneault J, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S. Technology in Parkinson‘s disease: Challenges and Opportunities. Movement Disorders. 2016 accepted.

Synofzik M, Klenk J, Srulijes K, Schatton C, Schwickert L, Maetzler W, Becker C. Ambulatory activity components deteriorate differently across neurodegenerative diseases: A cross-sectional sensor-based study. Neurodegenerative Diseases. 2016 accepted.

Wilke C, Preische O, Deuschle C, Maetzler W, Kuhle J, Synofzik M. Neurofilament light chain is elevated in FTD not only in cerebrospinal fluid, but also in serum. Journal of Neurology, Neurosurgery & Psychiatry. 2016 accepted.

Maetzler W, Rattay TW, Hobert MA, Synofzik M, Bader A, Berg D, Schaeffer E, Rommel N, Devos D, Bloem BR, Bender B. Freezing of Swallowing. Movement Disorders Clinical Practice. 2016 accepted.

Elshehabi M, Maier KS, Hasmann SE, Nussbaum S, Herbst H, Heger T, Berg D, Hobert MA, Maetzler W. Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. Front Aging Neurosci. 2016 8:4.

Pilotto A, Schulte C, Hauser AK, Biskup S, Munz M, Brockmann K, Schaeffer E, Synofzik M, Maetzler W, Suenkel U, Srulijes K, Gasser T, Berg D. GBA-associated parkinsonism and dementia: beyond alpha-synucleinopathies? Eur J Neurol. 2016 Mar;23(3):520-6.

Bernhard FP, Heinzel S, Binder G, Weber K, Apel A, Roeben B, Deuschle C, Maechtel M, Heger T, Nussbaum S, Gasser T, Maetzler W, Berg D. Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. PLoS One. 2016 11(3):e0150552.

Godinho C, Domingos J, Cunha G, Santos AT, Fernandes RM, Abreu D, Goncalves N, Matthews H, Isaacs T, Duffen J, Al-Jawad A, Larsen F, Serrano A, Weber P, Thoms A, Sollinger S, Graessner H, Maetzler W, Ferreira JJ. A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. J Neuroeng Rehabil. 2016 13(1):24.

van Lummel RC, Walgaard S, Hobert MA, Maetzler W, van Dieen JH, Galindo-Garre F, Terwee CB. Intra-Rater, Inter-Rater and Test-Retest Reliability of an Instrumented Timed Up and Go (iTUG) Test in Patients with Parkinson's Disease. PLoS One. 2016 11(3):e0151881.

Roeben B, Maetzler W, Vanmechelen E, Schulte C, Heinzel S, Stellos K, Godau J, Huber H, Brockmann K, Wurster I, Gaenslen A, Gruner E, Niebler R, Eschweiler GW, Berg D, TREND study team. Association of Plasma Abeta40 Peptides, But Not Abeta42, with Coronary Artery Disease and Diabetes Mellitus. J Alzheimers Dis. 2016 Mar 16.

Heinzel S, Maechtel M, Hasmann SE, Hobert MA, Heger T, Berg D, Maetzler W. Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. Parkinsonism Relat Disord. 2016 Mar 14.

Wilke C, Gillardon F, Deuschle C, Dubois E, Hobert MA, Vom Hagen JM, Kruger S, Biskup S, Blauwendraat C, Hruscha M, Kaeser S, Heutink P, Maetzler W, Synofzik M. Serum levels of progranulin do not reflect cerebrospinal fluid levels in neurodegenerative disease. Curr Alzheimer Res. 2016 Mar 14.

van Uem J, Isaacs T, Lewin A, Bresolin E, Salkovic D, Espay AJ, Matthews H, Maetzler W. A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. J Parkinsons Dis. 2016 Mar 10.

Yilmaz R, Behnke S, Liepelt-Scarfone I, Roeben B, Pausch C, Runkel A, Heinzel S, Niebler R, Suenkel U, Eschweiler GW, Maetzler W, Berg D. Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults. Eur J Neurol. 2016 May;23(5):973-8.

Santoro M, Maetzler W, Stathakos P, Martin HL, Hobert MA, Rattay TW, Gasser T, Forrester JV, Berg D, Tracey KJ, Riedel G, Teismann P. In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. Neurobiol Dis. 2016 Feb 24;91:59-68.

Ramsperger R, Meckler S, Heger T, van Uem J, Hucker S, Braatz U, Graessner H, Berg D, Manoli Y, Serrano JA, Ferreira JJ, Hobert MA, Maetzler W, Sense-Park study team. Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect. Parkinsonism Relat Disord. 2016 Feb 10.

Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, Nalls MA, Clark L, Honig L, Marder K, van der Flier W, Holstege H, Louwersheimer E, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns NJ, Halliday GM, Mann D, Pickering-Brown S, Powell J, Lunnon K, Lupton MK, International Parkinson's Disease Genomics C, Dickson D, Hardy J, Singleton A, Bras J. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol Aging. 2016 Feb;38:214 e7-14 e10.

van Uem JM, Marinus J, Canning C, van Lummel R, Dodel R, Liepelt-Scarfone I, Berg D, Morris ME, Maetzler W. Health-Related Quality of Life in patients with Parkinson's disease-A systematic review based on the ICF model. Neurosci Biobehav Rev. 2016 Feb;61:26-34.

Lawton M, Kasten M, May MT, Mollenhauer B, Schaumburg M, Liepelt-Scarfone I, Maetzler W, Vollstedt EJ, Hu MT, Berg D, Ben-Shlomo Y. Validation of conversion between mini-mental state examination and montreal cognitive assessment. Mov Disord. 2016 Apr;31(4):593-6.

Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C, Berg D, Ruschil C, Galata V, Ruprecht K, Stahler C, Wurstle M, Sickert D, Gogol M, Meder B, Meese E. Validating Alzheimer's disease micro RNAs using next-generation sequencing. Alzheimers Dement. 2016 Jan 22.

Goldeck D, Maetzler W, Berg D, Oettinger L, Pawelec G. Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. J Neuroimmunol. 2016 Jan 15;290:60-5.

Blauwendraat C, Wilke C, Jansen IE, Schulte C, Simon-Sanchez J, Metzger FG, Bender B, Gasser T, Maetzler W, Rizzu P, Heutink P, Synofzik M. Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. Neurobiol Aging. 2016 Jan;37:208 e11-7

 

2015

 

Maetzler W, Rochester L. Body-worn sensors--the brave new world of clinical measurement? Mov Disord. 2015 Aug;30(9):1203-5.

Coffee, Caffeine Genetics Consortium, Cornelis MC, Byrne EM, … International Parkinson's Disease Genomics Consortium, Chasman DI. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry. 2015 May;20(5):647-56.

Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, Saad M, Jansen I, Guerreiro R, Lubbe S, Plagnol V, Gibbs JR, Schulte C, Pankratz N, Sutherland M, Bertram L, Lill CM, DeStefano AL, Faroud T, Eriksson N, Tung JY, Edsall C, Nichols N, Brooks J, Arepalli S, Pliner H, Letson C, Heutink P, Martinez M, Gasser T, Traynor BJ, Wood N, Hardy J, Singleton AB, International Parkinson's Disease Genomics Consortium, Parkinson's Disease meta-analysis Consortium. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging. 2015 Mar;36(3):1605 e7-12.

Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, Brosseron F, Cavedo E, Fladby T, Froelich L, Gabryelewicz T, Gurvit H, Kapaki E, Koson P, Kulic L, Lehmann S, Lewczuk P, Lleo A, Maetzler W, de Mendonca A, Miller AM, Molinuevo JL, Mollenhauer B, Parnetti L, Rot U, Schneider A, Simonsen AH, Tagliavini F, Tsolaki M, Verbeek MM, Verhey FR, Zboch M, Winblad B, Scheltens P, Zetterberg H, Visser PJ. The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Front Neurol. 2015 6:216.

Lerche S, Liepelt-Scarfone I, Alves G, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Burn D, Dodel R, Grosset D, Heinzel S, Hu M, Kasten M, Kruger R, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Sunkel U, Walter U, Wirdefeldt K, Berg D. Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. Neuroepidemiology. 2015 Nov 3;45(4):282-97.

Brockmann K, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Parkinsonism Relat Disord. 2015 Dec;21(12):1427-34.

Srulijes K, Mack DJ, Klenk J, Schwickert L, Ihlen EA, Schwenk M, Lindemann U, Meyer M, K CS, Hobert MA, Brockmann K, Wurster I, Pomper JK, Synofzik M, Schneider E, Ilg U, Berg D, Maetzler W, Becker C. Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. BMC Neurol. 2015 15(1):192.

Heinzel S, Metzger FG, Ehlis AC, Korell R, Alboji A, Haeussinger FB, Wurster I, Brockmann K, Suenkel U, Eschweiler GW, Maetzler W, Berg D, Fallgatter AJ. Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. PLoS One. 2015 10(9):e0138863.

Ferreira JJ, Godinho C, Santos AT, Domingos J, Abreu D, Lobo R, Goncalves N, Barra M, Larsen F, Fagerbakke O, Akeren I, Wangen H, Serrano JA, Weber P, Thoms A, Meckler S, Sollinger S, van Uem J, Hobert MA, Maier KS, Matthew H, Isaacs T, Duffen J, Graessner H, Maetzler W. Quantitative home-based assessment of Parkinson's symptoms: the SENSE-PARK feasibility and usability study. BMC Neurol. 2015 15:89.

Sartorius T, Peter A, Heni M, Maetzler W, Fritsche A, Haring HU, Hennige AM. The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier? PLoS One. 2015 10(5):e0126804.

Maetzler W, Ellerbrock M, Heger T, Sass C, Berg D, Reilmann R. Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. PLoS One. 2015 10(4):e0123914.

Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, Jessen F, Herukka SK, Soininen H, Maetzler W, Leyhe T, Burger K, Taniguchi M, Urakami K, Lista S, Dubois B, Blennow K, Hampel H. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimers Dement. 2015 Nov;11(11):1306-15.

Synofzik M, Maetzler W. [Successful aging: what can neurology and geriatrics contribute?]. Nervenarzt. 2015 Apr;86(4):475-80.

Maetzler W, Drey M, Jacobs AH. [Sarcopenia and frailty in neurology]. Nervenarzt. 2015 Apr;86(4):420-30.

Schaeffer E, Maetzler W, Liepelt-Scarfone I, Sass C, Reilmann R, Berg D. Quantitative motor assessment of dyskinesias in Parkinson's disease. J Neural Transm (Vienna). 2015 Sep;122(9):1271-8.

Herfurth M, Godau J, Kattner B, Rombach S, Grau S, Maetzler W, Berg D. Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. Parkinsonism Relat Disord. 2015 doi:10.1016/j.parkreldis.2015.01.016.

Ferreira JJ, Santos AT, Domingos J, Matthews H, Isaacs T, Duffen J, Al-Jawad A, Larsen F, Artur Serrano J, Weber P, Thoms A, Sollinger S, Graessner H, Maetzler W. Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. J Parkinsons Dis. 2015 Jun 1;5(2):281-90.

Serrano JA, Larsen F, Isaacs T, Matthews H, Duffen J, Riggare S, Capitanio F, Ferreira JJ, Domingos J, Maetzler W, Graessner H. Participatory Design in Parkinson's Research with Focus on the Symptomatic Domains to be Measured. J Parkinsons Dis. 2015 Jan 1;5(1):187-96.

Hagen K, Ehlis AC, Haeussinger FB, Beeretz S, Kromer GV, Heinzel S, Maetzler W, Eschweiler GW, Berg D, Fallgatter AJ, Metzger FG, Consortium TS. The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. J Neural Transm (Vienna). 2015 Aug;122(8):1167-74.

Lerche S, Brockmann K, Wurster I, Gaenslen A, Roeben B, Holz D, Eschweiler GW, Maetzler W, Berg D. Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration? Parkinsonism Relat Disord. 2015 Feb;21(2):126-30.

Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015 Feb;36(2):1072-4.

Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D. GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord. 2015 Mar;30(3):407-11.

Laske C, Stellos K, Kempter I, Stransky E, Maetzler W, Fleming I, Randriamboavonjy V. Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. Alzheimers Dement. 2015 May;11(5):465-74.

Maetzler W, Karam M, Berger MF, Heger T, Maetzler C, Ruediger H, Bronzova J, Lobo PP, Ferreira JJ, Ziemssen T, Berg D. Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. J Neural Transm (Vienna). 2015 Mar;122(3):419-25.

Louter M, Maetzler W, Prinzen J, van Lummel RC, Hobert M, Arends JB, Bloem BR, Streffer J, Berg D, Overeem S, Liepelt-Scarfone I. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):32-7.

 

2014

 

Nalls MA, Pankratz N, Lill CM, …, International Parkinson's Disease Genomics Consortium, …, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014 Sep;46(9):989-93.

Graber S, Liepelt-Scarfone I, Csoti I, Maetzler W, Sultan F, Berg D. Post-cueing deficits with maintained cueing benefits in patients with Parkinson's disease dementia. Front Neurol. 2014 5:236.

Heinzel S, Gold M, Deuschle C, Bernhard F, Maetzler W, Berg D, Dodel R. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. PLoS One. 2014 9(12):e114566.

Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, Liepelt-Scarfone I, Schulte C, Reusch D, Schleicher E, Rothfuss O, Schneider A, Dodel R, Gasser T, Berg D. In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 alpha-synuclein antibody. Acta Neuropathol. 2014 Dec;128(6):893-5.

Hasmann SE, Berg D, Hobert MA, Weiss D, Lindemann U, Streffer J, Liepelt-Scarfone I, Maetzler W. Instrumented functional reach test differentiates individuals at high risk for Parkinson’s disease from controls. Front Aging Neurosc. 2014.

Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D, Kaminski CF, Winkler DT, Maetzler W, Keyvani K, Spitzer P, Wiltfang J, Kaminski Schierle GS, Zetterberg H, Staufenbiel M, Jucker M. Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal fluid. Brain. 2014 Nov;137(Pt 11):2909-15.

Heinzel S, Liepelt-Scarfone I, Roeben B, Nasi-Kordhishti I, Suenkel U, Wurster I, Brockmann K, Fritsche A, Niebler R, Metzger FG, Eschweiler GW, Fallgatter AJ, Maetzler W, Berg D. A neurodegenerative vascular burden index and the impact on cognition. Front Aging Neurosci. 2014 6:161.

Bras J, Guerreiro R, Darwent L, ..., Maetzler W, ..., Hardy J. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014 Dec 1;23(23):6139-46.

van der Zee J, Van Langenhove T, Kovacs GG, ... Maetzler W, ... Van Broeckhoven C. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol. 2014 Sep;128(3):397-410.

Benzinger P, Rapp K, Maetzler W, Konig HH, Jaensch A, Klenk J, Buchele G. Risk for femoral fractures in Parkinson's disease patients with and without severe functional impairment. PLoS One. 2014 9(5):e97073.

Heni M, Schopfer P, Peter A, Sartorius T, Fritsche A, Synofzik M, Haring HU, Maetzler W, Hennige AM. Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. Acta Diabetol. 2014 Aug;51(4):679-81.

Maetzler W. Comment: Why do nondopaminergic features in Parkinson disease matter? Neurology. 2014 Feb 4;82(5):417.

Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres MV, Gomez-Carrillo B, Leon T, Del Ser T, Tauros Investigators. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014 Apr;29(4):470-8.

Hoglinger GU, Huppertz HJ, Wagenpfeil S, Andres MV, Belloch V, Leon T, Del Ser T, Tauros Mri Investigators. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014 Apr;29(4):479-87.

Lerche S, Hobert MA, Brockmann K, Wurster I, Gaenslen A, Hasmann S, Eschweiler GW, Maetzler W, Berg D. Mild Parkinsonian Signs in the Elderly - Is There an Association with PD? Crossectional Findings in 992 Individuals. PLoS One. 2014 9(3):e92878.

Vijayaraghavan S, Maetzler W, Reimold M, Lithner CU, Liepelt-Scarfone I, Berg D, Darreh-Shori T. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. Alzheimers Dement. 2014 Sep;10(5):530-40 e1. *equal contribution.

Hobert MA, Maetzler W, Aminian K, Chiari L. Technical and clinical view on ambulatory assessment in Parkinson's disease. Acta Neurol Scand. 2014 Sep;130(3):139-47.

Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, Lerche S, Eschweiler GW, Maetzler W, Berg D. Prodromal features for Parkinson's disease--baseline data from the TREND study. Eur J Neurol. 2014 May;21(5):766-72.

Maetzler W, Apel A, Langkamp M, Deuschle C, Dilger SS, Stirnkorb JG, Schulte C, Schleicher E, Gasser T, Berg D. Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls. PLoS One. 2014 9(2):e88604.

Mielke MM, Maetzler W. A 'bird's eye' view on the current status and potential benefits of blood biomarkers for Parkinson's disease. Biomark Med. 2014 Feb;8(2):225-7.

 

2013

 

Liepelt-Scarfone I, Fruhmann Berger M, Prakash D, Csoti I, Graber S, Maetzler W, Berg D. Clinical Characteristics with an Impact on ADL Functions of PD Patients with Cognitive Impairment Indicative of Dementia. PLoS One. 2013 8(12):e82902.

Mielke MM*, Maetzler W*, Haughey NJ, Bandaru VV, Savica R, Deuschle C, Gasser T, Hauser AK, Graber-Sultan S, Schleicher E, Berg D, Liepelt-Scarfone I. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One. 2013 8(9):e73094. *equal contribution.

Liepelt-Scarfone I, Gauss K, Maetzler W, Muller K, Bormann C, Fruhmann Berger M, Timmers M, Streffer J, Berg D. Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: The Progression Markers in the Premotor Phase Study. Neuroepidemiology. 2013 Sep 17;41(3-4):174-82.

Maetzler W, Nieuwhof F, Hasmann SE, Bloem BR. Emerging therapies for gait disability and balance impairment: Promises and pitfalls. Mov Disord. 2013 Sep 15;28(11):1576-86.

Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord. 2013 Oct;28(12):1628-37.

Koehler NK, Stransky E, Shing M, ..., Maetzler W, ..., Richartz-Salzburger E. Altered Serum IgG Levels to alpha-Synuclein in Dementia with Lewy Bodies and Alzheimer's Disease. PLoS One. 2013 8(5):e64649.

Brockmann K, Schulte C, Hauser AK, Lichtner P, Huber H, Maetzler W, Berg D, Gasser T. SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord. 2013 Aug;28(9):1217-21.

Klenk J, Chiari L, Helbostad JL, Zijlstra W, Aminian K, Todd C, Bandinelli S, Kerse N, Schwickert L, Mellone S, Bagala F, Delbaere K, Hauer K, Redmond SJ, Robinovitch S, Aziz O, Schwenk M, Zecevic A, Zieschang T, Becker C, FARSEEING Consortium and the FARSEEING Meta-Database Consensus Group. Development of a standard fall data format for signals from body-worn sensors. Z Gerontol Geriatr. 2013 Dec;46(8):720-6.

Schwickert L, Becker C, Lindemann U, Marechal C, Bourke A, Chiari L, Helbostad JL, Zijlstra W, Aminian K, Todd C, Bandinelli S, Klenk J, FARSEEING Consortium and the FARSEEING Meta Database Consensus Group. Fall detection with body-worn sensors : a systematic review. Z Gerontol Geriatr. 2013 Dec;46(8):706-19.

Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, Siderowf A, Schapira AH, Oertel W, Obeso JA, Olanow CW, Poewe W, Stern M. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol. 2013 May;12(5):514-24.

Nalls MA, Duran R, Lopez G, …, Maetzler W, Brockmann K, Gasser T, …, Sidransky E. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013 Jun;70(6):727-35.

Srulijes K, Hauser AK, Guella I, Asselta R, Brockmann K, Schulte C, Solda G, Cilia R, Maetzler W, Schols L, Wenning GK, Poewe W, Barone P, Wullner U, Oertel W, Berg D, Goldwurm S, Gasser T. No association of GBA mutations and multiple system atrophy. Eur J Neurol. 2013 Apr;20(4):e61-2

Leyhe T, Darreh-Shori T, Laske C, Mielke MM, Maetzler W. Biomarkers in Alzheimer's disease and lewy body disorders with dementia. Int J Alzheimers Dis. 2013 2013:473181.

Liscic RM, Srulijes K, Groger A, Maetzler W, Berg D. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand. 2013 May;127(5):362-70.

Heinzel S, Metzger FG, Ehlis AC, Korell R, Alboji A, Haeussinger FB, Hagen K, Maetzler W, Eschweiler GW, Berg D, Fallgatter AJ, Consortium TS. Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. Neurobiol Aging. 2013 Feb;34(2):439-50.

van der Zee J, Gijselinck I, Dillen L, ..., Maetzler W, ..., Van Broeckhoven C. A Pan-European study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability and Intermediate Repeats. Hum Mutat. 2013 Feb;34(2):363-73.

Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W, the Psg. The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):102-8.

Laske C, Schmohl M, Leyhe T, Stransky E, Maetzler W, Berg D, Fallgatter AJ, Joos T, Dietzsch J. Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. J Alzheimers Dis. 2013 Jan 1;34(2):367-75

 

2012

 

Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, Melms A, Gasser T, Berg D. Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia. PLoS One. 2012 7(10):e48042.

Synofzik M, Maetzler W, Grehl T, Prudlo J, Vom Hagen JM, Haack T, Rebassoo P, Munz M, Schols L, Biskup S. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol Aging. 2012 Dec;33(12):2949 e13-7.

Maetzler W, Hausdorff JM. Reply: Presyndromic phase: Proposal for a new term for an emerging concept. Mov Disord. 2012 Oct;27(12):1584-5.

Deleidi M, Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis. 2012:391438.

Maetzler W, Klenk J, Becker C, Zscheile J, Gabor KS, Lindemann U. Longitudinal changes of nerve conduction velocity, distal motor latency, compound motor action potential duration, and skin temperature during prolonged exposure to cold in a climate chamber. Int J Neurosci. 2012 Sep;122(9):528-31.

Adame MR, Al-Jawad A, Romanovas M, Hobert MA, Maetzler W, Moller K, Manoli Y. TUG Test Instrumentation for Parkinson's disease patients using Inertial Sensors and Dynamic Time Warping. Biomed Tech (Berl). 2012 Aug 30.

Becker C, Schwickert L, Mellone S, Bagala F, Chiari L, Helbostad JL, Zijlstra W, Aminian K, Bourke A, Todd C, Bandinelli S, Kerse N, Klenk J, Consortium Group FMDC. Proposal for a multiphase fall model based on real-world fall recordings with body-fixed sensors. Z Gerontol Geriatr. 2012 Dec;45(8):707-15.

Sathe K*, Maetzler W*, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S, Synofzik M, Vukovic Z, Itohara S, Berg D, Teismann P. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain. 2012 Nov;135(Pt 11):3336-47. *equal contribution

Maetzler W, Mancini M, Liepelt-Scarfone I, Muller K, Becker C, van Lummel RC, Ainsworth E, Hobert M, Streffer J, Berg D, Chiari L. Impaired trunk stability in individuals at high risk for Parkinson's disease. PLoS One. 2012 7(3):e32240.

Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson's disease. Mov Disord. 2012 Apr 15;27(5):627-33.

Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, Gaenslen A, Huber H, Wurster I, Niebler R, Eschweiler GW, Berg D. Lowered Serum Amyloid-beta1-42 Autoantibodies in Individuals with Lifetime Depression. J Alzheimers Dis. 2012 Jan 1;32(1):95-100.

Srulijes K, Reimold M, Liscic RM, Bauer S, Dietzel E, Liepelt-Scarfone I, Berg D, Maetzler W. Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. Mov Disord. 2012 Jan;27(1):151-5.

Jamour M, Becker C, Synofzik M, Maetzler W. [Gait changes as an early indicator of dementia]. Z Gerontol Geriatr. 2012 Jan;45(1):40-4.

Liepelt-Scarfone I, Jamour M, Maetzler W. Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses. Z Gerontol Geriatr. 2012 Jan;45(1):23-33.

Schmid SP, Schleicher ED, Cegan A, Deuschle C, Baur S, Hauser AK, Synofzik M, Srulijes K, Brockmann K, Berg D, Maetzler W. Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Mov Disord. 2012 Feb;27(2):288-92.

Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stoffler A, Streffer J, Berg D. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm. 2012 Jan;119(1):39-52.

 

2011

 

Brockmann K, Groger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord. 2011 Nov;26(13):2335-42.

Hobert MA, Niebler R, Meyer SI, Brockmann K, Becker C, Huber H, Gaenslen A, Godau J, Eschweiler GW, Berg D, Maetzler W. Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study. PLoS One. 2011 6(11):e27831.

Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, Wurster I, Schleicher E, Melms A, Berg D. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis. 2011 27(1):119-26.

Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W. Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord. 2011 31(6):413-6.

Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol. 2011 Jul;68(7):932-7.

Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, Berg D. Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol. 2011 Jul;68(7):925-31.

Liepelt-Scarfone I, Graeber S, Feseker A, Baysal G, Godau J, Gaenslen A, Maetzler W, Berg D. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinsons Dis. 2011 2011:540843.

Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jul;43(7):699-705.

Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hornig S, Langkamp M. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis. 2011 26(1):171-9.

Srulijes K, Mallien G, Bauer S, Dietzel E, Groger A, Ebersbach G, Berg D, Maetzler W. In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. J Neural Transm. 2011 Aug;118(8):1191-7.

Klenk J, Becker C, Lieken F, Nicolai S, Maetzler W, Alt W, Zijlstra W, Hausdorff JM, van Lummel RC, Chiari L, Lindemann U. Comparison of acceleration signals of simulated and real-world backward falls. Med Eng Phys. 2011 Apr;33(3):368-73.

Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A, Gasser T, Berg D. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord. 2011 Jan;26(1):176-81.

Maetzler W, Reimold M, Schittenhelm J, Vorgerd M, Bornemann A, Kotter I, Pfannenberg C, Reischl G, Schols L. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1060-2.

Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, Dillmann U, Gaenslen A, Di Santo A, Maetzler W, Berg D. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging. 2011 Sep;32(9):1599-606.

 

2010

 

Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, Brockmann K, Melms A, Gasser T, Berg D. Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. J Alzheimers Dis. 2010 22(3):933-8.

Nicolai S, Mirelman A, Herman T, Zijlstra A, Mancini M, Becker C, Lindemann U, Berg D, Maetzler W. Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. Z Gerontol Geriatr. 2010 Aug;43(4):224-8.

Berg D, Seppi K, Liepelt I, Schweitzer K, Wollenweber F, Wolf B, Dillmann U, Stockner H, Godau J, Kiechl S, Gaenslen A, Willeit J, Di Santo A, Maetzler W, Gasser T, Poewe W, Behnke S. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord. 2010 Jul 30;25(10):1464-9.

Maetzler W, Berg D, Funke C, Sandmann F, Stunitz H, Maetzler C, Nitsch C. Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. Am J Pathol. 2010 Aug;177(2):829-39.

Laske C, Stransky E, Hoffmann N, Maetzler W, Straten G, Eschweiler GW, Leyhe T. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res. 2010 Aug;7(5):409-14.

Synofzik M, Fernandez-Santiago R, Maetzler W, Schols L, Andersen PM. The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):764-7.

Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, Huber H, Brockmann K, Gasser T, Berg D, Melms A. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis. 2010 19(3):937-42.

Lindemann U, Nicolai S, Beische D, Becker C, Srulijes K, Dietzel E, Bauer S, Berg D, Maetzler W. Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. Mov Disord. 2010 Jun 15;25(8):1040-6.

 

2009

 

Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009 Dec;8(12):1158-71.

Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J Alzheimers Dis. 2009 18(2):331-7.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, Herbst H, Berg D. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord. 2009 Jul 30;24(10):1504-11.

Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis. 2009 Aug;35(2):296-301.

Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T, Schulte C, Berg D. A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm. 2009 May;116(5):599-605.

Maetzler W, Stunitz H, Bendfeldt K, Vollenweider F, Schwaller B, Nitsch C. Microcalcification after excitotoxicity is enhanced in transgenic mice expressing parvalbumin in all neurones, may commence in neuronal mitochondria and undergoes structural modifications over time. Neuropathol Appl Neurobiol. 2009 Apr;35(2):165-77.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009 Apr;34(1):107-12.

 

Bis 2008

 

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008 Feb 1;39(3):1027-33.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors]. Nervenarzt. 2008 Jan;79(1):36-9, 42-6.

Maetzler W, Nagele T, Gasser T, Kruger R. Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology. 2007 Feb 6;68(6):414.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord. 2007 23(6):351-67.

Rossi C, Boss A, Lindig TM, Martirosian P, Steidle G, Maetzler W, Claussen CD, Klose U, Schick F. Diffusion tensor imaging of the spinal cord at 1.5 and 3.0 Tesla. Rofo. 2007 Mar;179(3):219-24.

Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T, Nitsch C. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis. 2007 Mar;25(3):473-82.

Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007 Aug;41(5):387-94.

Vollenweider F, Bendfeldt K, Maetzler W, Otten U, Nitsch C. GABA(B) receptor expression and cellular localization in gerbil hippocampus after transient global ischemia. Neurosci Lett. 2006 Mar 6;395(2):118-23.

Maetzler W, Nitsch C, Bendfeldt K, Racay P, Vollenweider F, Schwaller B. Ectopic parvalbumin expression in mouse forebrain neurons increases excitotoxic injury provoked by ibotenic acid injection into the striatum. Exp Neurol. 2004 Mar;186(1):78-88.

Haller R, Kemmler G, Kocsis E, Maetzler W, Prunlechner R, Hinterhuber H. [Schizophrenia and violence. Results of a comprehensive inquiry in an Austrian providence]. Nervenarzt. 2001 Nov;72(11):859-66.  

 

Buchkapitel und weitere Publikationen

 

Maetzler W, Grond M, Jacobs A. Neurogeriatrie. In: Hacke W, Neurologie. Springer, 14. Auflage, 2015

Srulijes K, Maetzler W. Progressive Supranuclear Palsy and Dementia. In: Martin C, Preedy V, editors. Diet and Nutrition Dementia and Cognitive Decline. Elsevier, 2015

Maetzler W, Synofzik M. Neurogeriatrie: eine zukunftsträchtige Disziplin zwischen Neurologie und Geriatrie. In: NeuroAktuell. 2014.

Maetzler W, Berg D. ApoE4 als Risikofaktor für die Alzheimer-Erkrankung. In: Labor&More. Vol. 1, 2014.

Lindner R, Anders J, Frilling B, Lukas A, Maetzler W, Bollheimer LC, Singler K. Depression, Suizidalität und Demenz im Alter. In: e.curriculum Geriatrie: Springer. 2013, p 1-37.

Maetzler W. Zukunft (in) der Neurogeriatrie. Current Congress. 2013, p 5.

Gasser T, Maetzler W. Molekulargenetik und Neurobiologie neurodegenerativer Demenzen. In: Wallesch C, Förstl H, editors. Demenzen. Stuttgart: Thieme. 2012. p 36-51.

Maetzler W. Die Prodromalphase des idiopathischen Parkinson-Syndroms. Psychiatrie & Neurologie. 03/2011, 13-15.

Maetzler W, Berg D. Biomarkers of Alzheimer's and Parkinson's Disease. In: Vaidya VS, Bonventre JV, editors. Biomarkers In Medicine, Drug Discovery, and Environmental Health. Hoboken, New Jersey: John Wiley and Sons, Inc. 2010. p 91-118.

Nicolai S, Hoffrichter R, Lindemann U, Maetzler W. Training mit Audio-Biofeedback. Robert-Bosch-Krankenhaus, Stuttgart: 2009.

Becker C, Nicolai S, Maetzler W, Pfeiffer K. Das SensAction-AAL-Projekt. Geriatrie Journal. 4/2009, 3333-34.

Synofzik M, Maetzler W. How should we treat dementia patients? The ethically problematic function of antidementia drugs. Ethik in der Medizin. 19/2007, 270-80.

Synofzik M, Maetzler W. Vignette: Fehlbehandlung eines Demenzkranken in einer psychiatrischen Klinik. Ethischer Kommentar. Zeitschrift für medizinische Ethik. 53/2007, 288-93.

Ambulanz für Neurogeriatrie

 

Die Ambulanz für Neurogeriatrie ist für ältere Patienten gedacht, bei denen alltagsrelevante Probleme mit Gang und Gleichgewicht auftreten (z.B. Stürze, Sturzangst), und eine neurologische Ursache (z.B. Konzentrationsstörung, "ungeschickt", "nicht mehr so schnell") nicht ausgeschlossen werden kann. Dies schließt Menschen mit neurodegenerativen Erkrankungen mit ein. Wir führen ein funktionelles Assessment mit moderner Sensortechnik durch, mit dem Ziel, den Betroffenen und Angehörigen praktisch anwendbare Empfehlungen und Therapieregimes mitzugeben.

Terminvereinbarung, Ansprechpartner und weitere Informationen finden Sie auf den Seiten der Ambulanz für Neurogeriatrie der Neurologischen Universitätsklinik Tübingen.

 

 

Forschungsgruppenleitung
Prof. Walter Maetzler walter.maetzler(at)uni-tuebingen.de Anschrift

Zentrum für Neurologie

Hertie-Institut für klinische Hirnforschung

Abteilung Neurologie mit Schwerpunkt neurodegenerative Erkrankungen

Hoppe-Seyler-Straße 3
72076 Tübingen

Tel.: +49 (0)7071 29-82047
Fax: +49 (0)7071 29-4596